Human Recombinant PCLAF protein, His Tag (V2LY-0526-LY5154)

Name: Human Recombinant PCLAF protein, His Tag
SKU: V2LY-0526-LY5154
Rating: 5 (1 reviews)

See all PCLAF antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

E. coli

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant PCLAF protein, His Tag consist of Amino Acid: 1-111 and predicts a molecular mass of 13.8 kDa.

Molecule Mass

13.8 kDa

Sequence

Amino Acid: 1-111

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

>97% as determined by SDS-PAGE

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile Tris, NaCl, Glycerol, Tween20

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

PCNA Clamp Associated Factor

Function

PCNA-binding protein that acts as a regulator of DNA repair during DNA replication. Following DNA damage, the interaction with PCNA is disrupted, facilitating the interaction between monoubiquitinated PCNA and the translesion DNA synthesis DNA polymerase eta (POLH) at stalled replisomes, facilitating the bypass of replication-fork-blocking lesions. Also acts as a regulator of centrosome number.

Biological Process

Cellular response to DNA damage stimulusManual Assertion Based On ExperimentIDA:UniProtKB
Centrosome cycleManual Assertion Based On ExperimentIMP:UniProtKB
DNA replicationManual Assertion Based On ExperimentIDA:UniProtKB
Regulation of cell cycleManual Assertion Based On ExperimentIMP:UniProtKB
Response to UVManual Assertion Based On ExperimentIDA:UniProtKB
Translesion synthesisManual Assertion Based On ExperimentIMP:UniProtKB

Cellular Location

Nucleus
Cytoplasm, perinuclear region
Following DNA damage, localizes to DNA damage sites (PubMed:21628590).
Colocalizes with centrosomes in perinuclear region (PubMed:21673012).

PTM

Monoubiquitinated at Lys-15 and Lys-24 during normal S phase, promoting its association with PCNA. Also diubiquitinated at these 2 sites. Following DNA damage, monoubiquitin chains at Lys-15 and Lys-24 are probably extended, leading to disrupt the interaction with PCNA. Polyubiquitinated by the APC/C complex at the mitotic exit, leading to its degradation by the proteasome.

Li, Y., Zeng, Z. W., Chen, D., Gu, Z. C., Yan, W. L., Yue, L. Y., ... & He, B. (2023). Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target. Journal of Medicinal Chemistry, 66(16), 11335-11350.

Liu, L., Lv, Z., Wang, M., Zhang, D., Liu, D., & Zhu, F. (2023). HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing. International Journal of Molecular Sciences, 24(4), 3263.

Liu, X., Cheng, C., Cai, Y., Gu, Y., Wu, Y., Chen, K., & Wu, Z. (2022). Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors. International Journal of Oncology, 60(6), 1-13.

Liu, X., Cai, Y., Cheng, C., Gu, Y., Hu, X., Chen, K., ... & Wu, Z. (2022). PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis. Cell death & disease, 13(2), 178.

Kim, B., Huang, Y., Ko, K. P., Zhang, S., Zou, G., Zhang, J., ... & Park, J. I. (2022). PCLAF-DREAM Drives Alveolar Cell Plasticity for Lung Regeneration. bioRxiv, 2022-10.

Magallanes-Garza, G. I., Santuario-Facio, S. K., Lira-Albarrán, S., Varela-Varela, A. F., Cardona-Huerta, S., Ruiz-Flores, P., ... & Ortiz-Lopez, R. (2022). NUSAP1 and PCLAF (KIA0101) downregulation by neoadjuvant therapy is associated with better therapeutic outcomes and survival in breast cancer. Journal of Oncology, 2022(1), 6001947.

Pan, L., Sha, J., Lin, W., Wang, Y., Bian, T., & Guo, J. (2021). Curcumin inhibits prostate cancer progression by regulating the miR‑30a‑5p/PCLAF axis. Experimental and Therapeutic Medicine, 22(3), 1-8.

Tantiwetrueangdet, A., Panvichian, R., Sornmayura, P., Leelaudomlipi, S., & Macoska, J. A. (2021). PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues. BMC cancer, 21, 1-12.

Ma, F., Zhi, C., Wang, M., Li, T., Khan, S. A., Ma, Z., ... & Ji, T. (2020). Dysregulated NF-κB signal promotes the hub gene PCLAF expression to facilitate nasopharyngeal carcinoma proliferation and metastasis. Biomedicine & Pharmacotherapy, 125, 109905.

Zhao, H., Zhang, W., Lai, X., Zhu, H., Zhang, S., Wu, W., ... & Tan, J. (2019). MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF. Artificial cells, nanomedicine, and biotechnology, 47(1), 278-289.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant PCLAF protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Recombinant Mouse Anti-PCLAF Recombinant Antibody (K11-P1G7) (CAT#: CBMAB-XB0909-YC)

Mouse Anti-PCLAF Recombinant Antibody (K11-P1G7/B8) (CAT#: CBMAB-P1057-YC)

Mouse Anti-PCLAF Recombinant Antibody (3C11-1F11) (CAT#: CBMAB-A4675-LY)

Mouse Anti-PCLAF Recombinant Antibody (3C11-1F11) (CAT#: CBMAB-K2189-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry